2023 World Conference on Lung Cancer (Posters)-P1.21. Prognostic Value of Change in Platelet Volume for Patients with Metastatic Non-small Cell Lung Cancer Treated with Pembrolizumab

P1.21. Prognostic Value of Change in Platelet Volume for Patients with Metastatic Non-small Cell Lung Cancer Treated with Pembrolizumab - PDF(Slides)

Back to course

Pdf Summary

A study conducted by researchers at The Ohio State University Comprehensive Cancer Center revealed that changes in platelet volume may serve as a prognostic indicator for patients with metastatic non-small cell lung cancer (NSCLC) who are receiving pembrolizumab-based therapy. Platelets play a significant role in immune response and can release immunosuppressive cytokines that affect the tumor's immune environment. The study analyzed 292 patients with metastatic NSCLC who were undergoing pembrolizumab treatment between 2017 and 2021. Baseline platelet count and mean platelet volume (MPV) were assessed, and MPV changes between the baseline and after the second cycle of treatment were recorded. The study found that an increase in MPV was associated with shorter overall survival in NSCLC patients. Additionally, thrombocytosis (platelet count over 450,000 /uL) and baseline platelet count were also linked to overall survival. Conversely, a decrease in mean platelet size after one cycle of pembrolizumab treatment was associated with improved overall survival. The study suggests that monitoring changes in platelet volume could serve as a valuable biomarker for monitoring the response to treatment and predicting outcomes in metastatic NSCLC patients. However, further research is needed to validate these findings and to explore potential mechanisms underlying platelet-related immune suppression in cancer. The study was supported by the National Institutes of Health and received additional support from the Pelotonia Institute of Immuno-Oncology.

Asset Subtitle

Mingjia Li

Meta Tag

Speaker Mingjia Li

Topic Pathology & Biomarkers: Biomarkers for Immuno-oncology

Keywords

platelet volume

prognostic indicator

metastatic non-small cell lung cancer

NSCLC

pembrolizumab-based therapy

immune response

immunosuppressive cytokines

baseline platelet count

mean platelet volume

overall survival